The following criteria is provided for health care professionals.

Inclusion Criteria:

• Part A:
  • Chronic Lymphocytic Leukemia
  • Hodgkin Lymphoma
  • Non Hodgkin Lymphoma
  • Multiple Myeloma
• Part B:
  • Chronic Lymphocytic Leukemia
  • Hodgkin Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
• Progressed, or been refractory to at least one prior standard therapy, including radiation, immunotherapy, cytotoxic chemotherapy, and select antibody (anti-CD20, Alemtuzumab, or Brentuximab) therapy
• Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving
• Subjects without prior exposure to immune cell modulating antibody regimens such as anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1), anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies. Prior anti-CD20, Alemtuzumab or Brentuximab antibody therapy is allowed
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• At least 1 lesion with measurable disease
• Willing to consent to allow a pre-treatment bone marrow biopsy
• Willing to consent to a pre-treatment tumor biopsy or allow the acquisition of an existing tumor sample

Exclusion Criteria:

• Primary cutaneous lymphoma, lymphoproliferative diseases associated with primary immune deficiencies, and lymphomas associated with human immunodeficiency virus (HIV) infection
• Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia
• MGUS, smoldering myeloma or Waldenström's macroglobulinuria
• Active plasma cell leukemia
• Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease (controlled CNS metastases are allowed)
• Autoimmune disease